Bolt Biotherapeutics Inc (BOLT)

$5.44 -0.42 (-7.17%)
Market Cap 10.44M
Revenue (ttm) 7.69M
Net Income (ttm) -63.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -820.81%
Debt to Equity Ratio 0.00
Volume 74,200
Avg Vol 43,586
Day's Range N/A - N/A
Shares Out 1.92M
Stochastic %K 43%
Beta 0.93
Analysts Sell
Price Target $6.00

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 665 9295
Address:
900 Chesapeake Drive, Redwood City, United States
skyrockets_Inc
skyrockets_Inc Dec. 12 at 6:02 PM
$BOLT I just bought another 1k shares myself. Only stock on my watchlist that is green today, everything else is blood red.
1 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 12 at 5:59 PM
$BOLT Continuing my historical analysis the price is moving solidly as predicted. 50 and 100 day SMA about to cross, stock looks to be heading to 6.50-6.60 range next. Then after that the sky is the limit :) Good luck BOLTERS
0 · Reply
MindfulMonkey
MindfulMonkey Dec. 12 at 5:20 PM
$BOLT I thought this would drop due to profit taking and it being Friday. Turns out people are instead loading. I'm super excited for Monday. I think Christmas is about to pay for itself 😉
1 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 9 at 8:21 PM
$BOLT ChatGPT thinks Regeneron is a likely candidate to partner/buyout BDC-3042. BOLT's BDC-3042 is a Dectin 2 agonist that it meant to be used in combination with PD-1 inhibitors (such as Regeneron's cemiplimab), not as a monotherapy. BOLT initiated a partnering process back in April for BDC-3042 and requested non binding term sheets by June. This process is likely still ongoing and it would make more sense IMO for Regeneron to just buy BOLT out directly at these levels rather than partnering. We shall see. The sky is the limit !
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 9 at 3:59 PM
$BOLT The 50 and 100 SMA about to converge. Stock price is trading tightly within. Major move coming soon IMO. Yesterday AH's move to 7.30 is going to look like child's play. Only 1.92m OS, $15/share in cash alone, and 50% tute/insider ownership. No dilution risk either. Jupiter soon.
1 · Reply
SheriffGrover
SheriffGrover Dec. 9 at 1:27 PM
$BOLT So ...... (correct me if I'm wrong) Yesterday after hours $ 7.30 on 300 K shares and now pre market down 6 % to $5.05 .... Beats me .............
2 · Reply
JDD808
JDD808 Dec. 8 at 11:21 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 8 at 10:42 PM
$BOLT patent news triggered scanners and only 300k shares took it to 7.30/share....imagine what happens when real news drops . Just shows the power and fuel behind this rocket ship that I've been talking about for months :)
1 · Reply
foundghost
foundghost Dec. 8 at 10:42 PM
$BOLT
0 · Reply
DaBullRunner
DaBullRunner Dec. 8 at 10:41 PM
$BOLT watching 🚨KITT🚨 will be my next MONSTER SOON THIS WILL CATCH FIRE AND RUN LIKE $RR $SERV as it is lagging behind them heavily $ORKT $AQB let’s go
0 · Reply
Latest News on BOLT
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 4 weeks ago

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Oct 1, 2025, 4:05 PM EDT - 2 months ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:05 PM EDT - 4 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 7 months ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

May 8, 2025, 8:00 AM EDT - 7 months ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 30, 2025, 4:05 PM EDT - 8 months ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 24, 2025, 4:20 PM EDT - 9 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Feb 25, 2025, 4:05 PM EST - 10 months ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Feb 11, 2025, 4:05 PM EST - 10 months ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 4, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 2, 2024, 11:11 AM EDT - 1 year ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 31, 2024, 11:25 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 31, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 29, 2024, 8:49 PM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Aug 27, 2024, 11:00 AM EDT - 1 year ago

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 26, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Jul 19, 2024, 11:10 AM EDT - 1 year ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jul 3, 2024, 4:47 PM EDT - 1 year ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jun 24, 2024, 3:36 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:37 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

skyrockets_Inc
skyrockets_Inc Dec. 12 at 6:02 PM
$BOLT I just bought another 1k shares myself. Only stock on my watchlist that is green today, everything else is blood red.
1 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 12 at 5:59 PM
$BOLT Continuing my historical analysis the price is moving solidly as predicted. 50 and 100 day SMA about to cross, stock looks to be heading to 6.50-6.60 range next. Then after that the sky is the limit :) Good luck BOLTERS
0 · Reply
MindfulMonkey
MindfulMonkey Dec. 12 at 5:20 PM
$BOLT I thought this would drop due to profit taking and it being Friday. Turns out people are instead loading. I'm super excited for Monday. I think Christmas is about to pay for itself 😉
1 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 9 at 8:21 PM
$BOLT ChatGPT thinks Regeneron is a likely candidate to partner/buyout BDC-3042. BOLT's BDC-3042 is a Dectin 2 agonist that it meant to be used in combination with PD-1 inhibitors (such as Regeneron's cemiplimab), not as a monotherapy. BOLT initiated a partnering process back in April for BDC-3042 and requested non binding term sheets by June. This process is likely still ongoing and it would make more sense IMO for Regeneron to just buy BOLT out directly at these levels rather than partnering. We shall see. The sky is the limit !
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 9 at 3:59 PM
$BOLT The 50 and 100 SMA about to converge. Stock price is trading tightly within. Major move coming soon IMO. Yesterday AH's move to 7.30 is going to look like child's play. Only 1.92m OS, $15/share in cash alone, and 50% tute/insider ownership. No dilution risk either. Jupiter soon.
1 · Reply
SheriffGrover
SheriffGrover Dec. 9 at 1:27 PM
$BOLT So ...... (correct me if I'm wrong) Yesterday after hours $ 7.30 on 300 K shares and now pre market down 6 % to $5.05 .... Beats me .............
2 · Reply
JDD808
JDD808 Dec. 8 at 11:21 PM
$BOLT
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 8 at 10:42 PM
$BOLT patent news triggered scanners and only 300k shares took it to 7.30/share....imagine what happens when real news drops . Just shows the power and fuel behind this rocket ship that I've been talking about for months :)
1 · Reply
foundghost
foundghost Dec. 8 at 10:42 PM
$BOLT
0 · Reply
DaBullRunner
DaBullRunner Dec. 8 at 10:41 PM
$BOLT watching 🚨KITT🚨 will be my next MONSTER SOON THIS WILL CATCH FIRE AND RUN LIKE $RR $SERV as it is lagging behind them heavily $ORKT $AQB let’s go
0 · Reply
JDD808
JDD808 Dec. 8 at 10:41 PM
$BOLT ayy what did I miss? still holding full
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 8 at 10:22 PM
$BOLT Only 300k shares made it pop to 7.30. Imagine what happens when millions come in. Float is only 1.92m . Rockets soon!
0 · Reply
JL_TradeZ
JL_TradeZ Dec. 8 at 10:16 PM
$BOLT 🔥
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 8 at 10:08 PM
$BOLT Flying!
0 · Reply
MHM7700
MHM7700 Dec. 8 at 10:04 PM
$BOLT short @ 7.24 PT @ 6.50 - 6.25 - below 6.25 SL @ 7.50
0 · Reply
PatentGrants
PatentGrants Dec. 8 at 10:00 PM
$BOLT Bolt Biotherapeutics has received a Notice of Allowance for a US patent titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)". https://patentcenter.uspto.gov/applications/17618729/ifw/docs
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 5 at 4:49 PM
$BOLT Just to give perspective, $BCAB initiated partnering discussing in Q1 2025 and are just now finalizing a partnership by end of year. Over a 9-10 month process. Their stock has risen likely to bake in part of this partnership news, whereas ours is still at lows...once our announcement comes out of nowhere it's firework central. 1.92m share OS. $15/share in cash. 50% tute and insider owned. Big pharma partnerships already in place w/ Genmab and Toray for multiple assets w/ BDC-3142 in Phase 1 trial ongoing.
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 5 at 4:02 PM
$BOLT Term sheets were due June 6. Based on previous stocks I've been in that had term sheets due this process takes A LONG time. Sometimes 6-8 months...so it's possible we could get on update on this soon as we are at the 6 month mark. I did send an email to IR in early October and they said 'there are no updates right now, but we continue to have discussions....' An out-right takeover of the company at these low prices makes more sense than a partnership. Maybe there's more to this than meets the eye. $15/share in cash and multiple promising assets . Fireworks soon IMO.
0 · Reply
MindfulMonkey
MindfulMonkey Dec. 5 at 3:42 PM
$BOLT interesting going into the end of Friday that it keeps trying to push back up. Buyers are stepping in... on Thursday and Friday, right before Christmas... into a biotech. Maybe a partnership IS coming by the end of this year. People loading before Monday open?
2 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 4 at 5:45 PM
$BOLT Well my prediction below was spot on. The re-trace to 5.40+ is complete. Let's see if we can hold and moon from here.
0 · Reply
JDD808
JDD808 Dec. 4 at 4:56 PM
$BOLT tape slightly active, please moon soon
0 · Reply
skyrockets_Inc
skyrockets_Inc Dec. 2 at 6:22 PM
$BOLT When expectations become the lowest is when these low floaters tend to explode. Just adding more shares weekly until then. Locked and BOLTED in w my fellow BOLTS.
0 · Reply